UDG shares have tripled over the past five years, but the best may be yet to come

The company has travelled a long road since its transition from United Drug

2nd October, 2016
UDG chief executive Brendan McAtamney Picture: Fergal Phillips

The ace cards that have delivered spectacular returns for UDG shareholders over the past five years have been the company’s high calibre and experienced acquisition team; its strategic and financially disciplined approach to choosing acquirees that have real sources of competitive advantage and pricing power and can be realistically targeted to deliver double-digit to mid-teen returns on capital employed, and management’s proven expertise in integration and innovation, as well as building business models that create...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Get basic

*New subscribers only

You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

Private rental sector remains strong despite Covid-19

How the programme for government will shape housing

Insight Niall Byrne 4 months ago

Comment: US must defuse Covid-19’s ticking time bomb of debt

Insight Todd G Buchholz 5 months ago

Comment: The recovery will be more U than V-shaped

Insight Larry Hatheway 5 months ago